-+ 0.00%
-+ 0.00%
-+ 0.00%

Kingsley Biotech (01548): Legend announced that the report will be presented at the 2025 ASH Annual Meeting

Zhitongcaijing·12/07/2025 11:09:04
Listen to the news

Zhitong Finance App News, Kingsley Biotech (01548) issued an announcement. Legend Biotech Co., Ltd. (“Legend”, an associated company, and its shares are listed on the US NASDAQ Global Select Market in the form of American Depositary Shares) issued a press release on December 6, 2025 (New York time) announcing the publication of CARVYKTI (“American Society of Hematology”) in patients with recurrent or refractory multiple myeloma (RRMM) through an oral report at the 2025 American Society of Hematology (“American Society of Hematology”) annual meeting Clinical and translational study data for long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies carried out,

In addition to the latest results of the phase III study CARTITUDE-4, CARVYKTI's mitigation persistence data and real-world research results in different subgroups were also presented through six posters. Legend also presented the first human test data for LUCAR-G39D, a dual-target allogeneic CAR-T candidate product, through an oral report at the American Society of Hematology's annual meeting.